Tevogen Bio (NASDAQ:TVGN – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($1.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.56) by $0.80, FiscalAI reports.
Tevogen Bio Stock Performance
Tevogen Bio stock traded down $0.40 during mid-day trading on Tuesday, hitting $5.82. 399 shares of the company traded hands, compared to its average volume of 20,245. The stock has a fifty day moving average price of $6.72 and a 200-day moving average price of $7.68. The stock has a market cap of $37.89 million, a price-to-earnings ratio of -1.26 and a beta of 0.21. Tevogen Bio has a one year low of $3.64 and a one year high of $24.91.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $100.00.
Get Our Latest Stock Analysis on TVGN
Tevogen Bio Company Profile
Tevogen Bio is a clinical-stage biotechnology company developing cell-based immunotherapies. Its ExacTcell platform uses donor-derived, antigen-specific T cells designed to recognize and attack disease-associated targets, with the goal of making therapies available without creating a custom treatment for each patient. The company’s lead investigational candidate, TVGN 489, is a T-cell therapy being developed for COVID-19. Tevogen is also pursuing potential applications of its platform in cancer and other diseases.
Further Reading
- Five stocks we like better than Tevogen Bio
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
